Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 in Chinese Men and Women With Parkinson's Disease
NCT07513441Phase 1Recruiting
- Sponsor
- Lundbeck
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 60 days, Area Under the Plasma Concentration-time Curve From Zero to Last Quantifiable Concentration at Day 41 and 2 more. Started May 2026; status: recruiting.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07513441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513441.